Alogliptin: Safety, Efficacy, and Clinical Implications

Conclusion: Alogliptin alone or in combination with other antidiabetic agents has shown a significant reduction in HbA1c while remaining safe and tolerable. The efficacy profile of alogliptin is comparable to other DPP-4 inhibitors. Additional long-term research is necessary with regard to long-standing efficacy and effects on beta-cell function.

Source: Journal of Pharmacy Practice - February 24, 2015 Category: Drugs & Pharmacology Authors: Marino, A. B., Cole, S. W. Tags: Review Article Source Type: research